Thought Disorder as a Neglected Dimension in Schizophrenia
- PMID: 36425242
- PMCID: PMC9674097
- DOI: 10.1530/alphapsychiatry.2021.21371
Thought Disorder as a Neglected Dimension in Schizophrenia
Abstract
Thought disorder (TD) is one of the main symptom domains of schizophrenia. TD is a construct that can be seen in both acute and chronic periods in patients with schizophrenia. It is associated with a poor prognosis and relapses, and it disrupts social-occupational functioning. TD also shows a strong familial aggregation and increases the risk of transition to schizophrenia in subjects with ultra-high risk. Although TD was once thought to be pathognomonic to schizophrenia, now it is known that it is a transdiagnostic symptom that is seen not only in schizophrenia but also in other psychiatric disorders. This article reviews the concept of thought disorder in terms of its history, clinical evaluation, neurocognitive features and clinical course in patients with schizophrenia.
Keywords: Prognosis, psychosocial functioning, remission, schizophrenia, thought.
© Copyright 2021 authors.
Conflict of interest statement
Conflict of Interest: The authors have no conflict of interest to declare.
Similar articles
-
Thought disorder and psychosocial functioning in schizophrenia: the concurrent and predictive relationships.J Nerv Ment Dis. 1999 May;187(5):281-9. doi: 10.1097/00005053-199905000-00003. J Nerv Ment Dis. 1999. PMID: 10348082
-
[Symptomatic remission and its relationship to social functioning in Tunisian out-patients with schizophrenia].Encephale. 2019 Feb;45(1):15-21. doi: 10.1016/j.encep.2017.09.005. Epub 2017 Nov 28. Encephale. 2019. PMID: 29195805 French.
-
A comparative study of childhood/adolescent and adult onset schizophrenia: does the neurocognitive and psychosocial outcome differ?Asian J Psychiatr. 2019 Jun;43:160-169. doi: 10.1016/j.ajp.2019.05.031. Epub 2019 May 20. Asian J Psychiatr. 2019. PMID: 31176081
-
[The cognitive paradigm in the rehabilitation of schizophrenia - focusing on cognitive remediation].Neuropsychopharmacol Hung. 2015 Sep;17(3):129-40. Neuropsychopharmacol Hung. 2015. PMID: 26485743 Review. Hungarian.
-
[Advocacy for the establishment of a comprehensive strategy to reduce the "burden" of schizophrenic disorders].Encephale. 2016 Oct;42(5):476-483. doi: 10.1016/j.encep.2016.05.007. Epub 2016 Sep 9. Encephale. 2016. PMID: 27623121 Review. French.
Cited by
-
Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.Clin Drug Investig. 2024 Jul;44(7):471-493. doi: 10.1007/s40261-024-01377-9. Epub 2024 Jun 21. Clin Drug Investig. 2024. PMID: 38904739 Review.
-
Deep transcranial magnetic stimulation for schizophrenia: a systematic review.Front Psychiatry. 2024 May 31;15:1390913. doi: 10.3389/fpsyt.2024.1390913. eCollection 2024. Front Psychiatry. 2024. PMID: 38881546 Free PMC article.
-
Transcranial alternating current stimulation for schizophrenia: a systematic review of randomized controlled studies.Front Psychiatry. 2024 Jan 11;14:1308437. doi: 10.3389/fpsyt.2023.1308437. eCollection 2023. Front Psychiatry. 2024. PMID: 38274423 Free PMC article.
-
Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder.Curr Neuropharmacol. 2025;23(8):996-1006. doi: 10.2174/011570159X350599241214042724. Curr Neuropharmacol. 2025. PMID: 39819543 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources